Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin/metformin - Boehringer Ingelheim/Eli Lilly

Drug Profile

Empagliflozin/metformin - Boehringer Ingelheim/Eli Lilly

Alternative Names: BI-10773/metformin; Empagliflozin/metformin extended-release; Empagliflozin/metformin immediate-release; Gibtulio Met; Metformin/BI-10773; Metformin/empagliflozin; Metformin/empagliflozin extended-release; Metformin/empagliflozin immediate-release; Metformin/empagliflozin XR; Synjardy; Synjardy XR

Latest Information Update: 30 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Eli Lilly
  • Class Antihyperglycaemics; Benzhydryl compounds; Biguanides; Cyclic ethers; Glucosides; Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 30 Jan 2019 Chemical structure information added
  • 15 Aug 2018 Depomed is now called Assertio Therapeutics
  • 11 Jul 2018 Boehringer Ingelheim and Lupin agree to market empagliflozin/metformin in India for Type-2 diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top